Insulin Resistance Reversed by Removal of Protein

By removing the protein galectin-3 (Gal3), a team of investigators led by University of California School of Medicine researchers were able to reverse diabetic insulin resistance and glucose intolerance in mouse models of obesity and diabetes. … Read the Full Story from the UC San Diego Newsroom


Dr. Jerrold Olefsky

Dr. Jerrold Olefsky

Dr. Jerrold Olefsky, Professor of Medicine in the Division of Endocrinology and Metabolism in the School of Medicine at UC San Diego, is principal investigator of this international study.

Read the Study Report (Full Content, UCSD Only)

See Dr. Olefsky’s Research Profile

New Institute for Diabetes and Metabolic Health Debuts at UC San Diego

Expansive effort will encompass both research and treatment of major national health issue —

The University of California San Diego School of Medicine has launched the Institute for Diabetes and Metabolic Health (IDMH), a new cross-disciplinary, collaborative effort to address one of the nation’s leading public health threats.

“Diabetes and other metabolic disorders pose an immense, perhaps unprecedented, health threat to virtually everyone,” said Alan Saltiel, PhD, IDMH director and one of the nation’s leaders in the study of metabolic disorders. “Tens of millions of Americans of all ages are already afflicted so the imperative is great to understand better these chronic, life-threatening conditions and find new ways to treat and prevent them.” … Read the Full Story from the UC San Diego Newsroom


Alan Saltiel, PhD

Alan Saltiel, PhD

IDMH Director Alan Saltiel, PhD, is Professor of Medicine in the Division of Endocrinology and Metabolism.

— Read his UCSD Profile
— Visit the Saltiel Laboratory website
— Visit the Institute for Diabetes and Metabolic Health website

Diabetes Drug Found No Better Than Placebo at Treating NAFLD

But randomized, double-blind clinical trial suggests better way to conduct future trials —

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.

Writing in the Journal of Hepatology, a multidisciplinary team headed by study senior author Rohit Loomba, MD, professor of medicine in the Division of Gastroenterology and director of the NAFLD Translational Research Unit at UC San Diego School of Medicine … Read the full story from the UC San Diego Newsroom

Novel 3D Imaging Offers New Tool for Identifying Advanced Fibrosis in Liver

UC San Diego School of Medicine NAFLD Research Center finds MRE imaging provides highly accurate, less invasive method —

Nonalcoholic fatty liver disease, or NAFLD, comprises a group of liver disorders whose prevalence is widespread and rising. It’s estimated that at least one-third of Americans have NAFLD; among obese persons, the figure is 50 percent. … Read the Full Story from the UC San Diego Newsroom


Rohit Loomba, MD, MHSc

Rohit Loomba, MD, MHSc

Rohit Loomba, MD, MHSc, Director of the NAFLD Research Center, is first author of the study report in The American Journal of Gastroenterology.

Dr. Loomba is Professor of Medicine in the Division of Gastroenterology, Department of Medicine; and Adjunct Professor in the Division of Epidemiology, Department of Family and Preventive Medicine.

New UC San Diego Center Will Focus on Heart Health Among Latinas

Researchers at the University of California, San Diego School of Medicine have launched a new four-year, $3.7 million multidisciplinary research center to investigate the relationship between sedentary behavior and cardiovascular risk factors in Latinas, who have a disproportionately higher chance of developing heart disease than the general population.

The study is part of a new Strategically Focused Research Network created and funded by the American Heart Association (AHA). … Read the Full Story from the UC San Diego Newsroom


Dorothy Sears, PhD

Dorothy Sears, PhD

Within the multidisciplinary research center, Dorothy Sears, PhD, Associate Professor of Medicine in the Division of Endocrinology & Metabolism, will conduct studies to find and characterize biomarkers of cardiovascular disease risk associated with sedentary behavior.

Short Overnight Fasting Linked to Increased Risk of Breast Cancer Recurrence

Researchers suggest increasing duration of nightly fasting may improve prognosis —

In patients with breast cancer, a short overnight fast of less than 13 hours was associated with a statistically significant, 36 percent higher risk of breast cancer recurrence and a non-significant, 21 percent higher probability of death from the disease compared to patients who fasted 13 or more hours per night, report University of California, San Diego School of Medicine researchers.

The study, publishing online in the Journal of the American Medical Association Oncology on March 31 … Read the Full Story from the UC San Diego Newsroom

Altman Clinical and Translational Research Building Makes Its Debut

New structure will be campus hub for advancing basic science to clinical applications —

Rising above Interstate 5 on the east campus of UC San Diego, the Altman Clinical and Translational Research Institute Building (ACTRI) officially opened its doors Friday in a ribbon-cutting ceremony under blue skies.

The new seven-story building of steel, glass and grooved concrete is home to the Clinical and Translational Research Institute (CTRI) at UC San Diego, established in 2010 as part of a national consortium of 60 medical research institutions created to energize bench-to-bedside efforts. … Read the Full Story from the UC San Diego Newsroom

Altman Clinical and Translational Research Institute Building Opens March 4

Stunning structure will house array of scientists and centers dedicated to speeding basic research into new treatments and therapies —

Rising above Interstate 5 on the east campus of University of California, San Diego, the Altman Clinical and Translational Research Institute Building (ACTRI), a five-sided polygon of glass, steel and grooved concrete, officially opens its doors March 4 in a ribbon-cutting ceremony.

“The building is an architectural marvel, but more important is what it represents and the work that will go on inside,” said UC San Diego Chancellor Pradeep K. Khosla. … Read the Full Story from the UC San Diego Newsroom


Dr. Gary Firestein

Dr. Gary Firestein

The director of the Clinical and Translational Research Institute at UC San Diego is Gary S. Firestein, MD, Professor of Medicine and Dean and Associate Vice Chancellor of Translational Medicine at UC San Diego.

CTRI opened in 2010 as a part of the national Clinical and Translational Science Award consortium through a five-year, $37.2 million grant from the National Center for Advancing Translational Science of the National Institutes of Health. CTRI received a $52 million renewal grant last year.

More about the activities of the CTRI

 

Fatty Liver Disease and Scarring Have Strong Genetic Component

Researchers at the University of California, San Diego School of Medicine say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.

The findings are published online in the journal Gastroenterology. … Read the Full Story from the UC San Diego Newsroom